Stocks Health care OSTX
NYSE · Health careOS Therapies Inc (OSTX)
It posted a net loss of $39.4M. In fiscal 2025 capital spending exceeded operating cash flow by $14.7M. At June 30, 2026 it held $205K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about OS Therapies Inc
- Net worth
- OS Therapies Inc has a market value (market cap) of $41.2M at the latest share price, and shareholders' equity of -$11.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $14.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- OS Therapies Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What OS Therapies Inc does
OS Therapies Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker OSTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$28.8M | -$0.98 | -$14.7M |
| 2024 | n/a | -$8.9M | -$1.28 | n/a |
| 2024 | n/a | -$7.8M | -$2.12 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What OS Therapies Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Executive or director change8-KOS Therapies appointed Frank Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer.
- September 21, 2026
- September 10, 2026Other event 8-K
- September 9, 2026
- August 21, 2026
- August 14, 2026
- August 12, 2026
- August 6, 2026
- July 29, 2026
- July 24, 2026
Insider trades
What the people running OS Therapies Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns OSTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ayala Pharmaceuticals, Inc.13G, passive | 9.99% | April 16, 2025 |
| Thomas A. Satterfield, Jr.13G, passive | 9.4% | August 13, 2025 |
| Shalom Auerbach13D, may seek influence with 1 related filers | 8.5% | August 18, 2025 |
Largest institutional holders
Insiders
Questions about OSTX
What does OS Therapies Inc do?
OS Therapies Inc is a company in the Health care sector, listed on NYSE as OSTX. Its shares trade on NYSE under the ticker OSTX.
What is OS Therapies Inc's net worth?
OS Therapies Inc has a market value (market cap) of $41.2M at the latest share price, and shareholders' equity of -$11.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is OS Therapies Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $39.4M.
When did OS Therapies Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 5, 2026.
When is OS Therapies Inc's next earnings report?
OS Therapies Inc's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare OSTX with
Follow OSTX
Get an email when OS Therapies Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values OS Therapies Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.